RT Journal Article
SR Electronic
T1 SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20105486
DO 10.1101/2020.05.21.20105486
A1 ,
A1 Andersson, Monique I
A1 Arancibia-Cárcamo, Carolina V
A1 Auckland, Kathryn
A1 Baillie, J Kenneth
A1 Barnes, Eleanor
A1 Beneke, Tom
A1 Bibi, Sagidi
A1 Carroll, Miles
A1 Crook, Derrick
A1 Dingle, Kate
A1 Dold, Christina
A1 Downs, Louise O
A1 Dunn, Laura
A1 Eyre, David W
A1 Jaramillo, Javier Gilbert
A1 Harvala, Heli
A1 Hoosdally, Sarah
A1 Ijaz, Samreen
A1 James, Tim
A1 James, William
A1 Jeffery, Katie
A1 Justice, Anita
A1 Klenerman, Paul
A1 Knight, Julian
A1 Knight, Michael
A1 Liu, Xu
A1 Lumley, Sheila F
A1 Matthews, Philippa C
A1 McNaughton, Anna L
A1 Mentzer, Alexander J
A1 Mongkolsapaya, Juthathip
A1 Oakley, Sarah
A1 Oliveira, Marta S
A1 Peto, Timothy
A1 Ploeg, Rutger J
A1 Ratcliff, Jeremy
A1 Roberts, David J
A1 Rudkin, Justine
A1 Screaton, Gavin
A1 Semple, Malcolm G
A1 Skelley, Donal
A1 Simmonds, Peter
A1 Stoesser, Nicole
A1 Turtle, Lance
A1 Wareing, Sue
A1 Zambon, Maria
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.21.20105486.abstract
AB Background Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood.Methods We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=212 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples.Results We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across clinical and convalescent samples collected ≥28 days post symptom onset, 0/244 (0%, 95%CI 0.0-1.5%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA.Conclusions vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.Competing Interest StatementDWE has received personal fees from Gilead, outside the submitted workFunding StatementThis work is supported by the following funding: National Institute for Health Research [award CO-CIN-01], Medical Research Council [grant MC_PC_19059], Sepsis Immunomics funding from the Wellcome Trust [204969/Z/16/Z)] National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], The Bill and Melinda Gates Foundation [OPP1209135], Liverpool Experimental Cancer Medicine Centre (infrastructure support) [ref: C18616/A25153]. TB, CVA-C, PCM, PK and DC received funding from NIHR Oxford Biomedical Research Centre. DWE is a Robertson Foundation Fellow. PCM and LT hold Wellcome fellowships [ref 110110/Z/15/Z and 205228/Z/16/Z respectively]. EB is an NIHR Senior Investigator. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Acute hospital in-patients were recruited into the Sepsis Immunomics study (Ref: 19/SC/0296). Convalescent healthcare workers with hospital encounters (n=38) and convalescent patients (n=32) provided informed consent for recruitment into the ISARIC WHO Clinical Characterisation Protocol UK (ISARIC WHO CCP-UK), with ethics approval by the South Central (Oxford C) Research Ethics Committee in England (Ref: 13/SC/0149), and Scotland A Research Ethics Committee in Scotland (Ref: 20/SS/0028). Additional convalescent healthcare workers were recruited by the Oxford GI Biobank, n=3 (approval by Yorkshire and The Humber - Sheffield Research Ethics Committee, ref. 16/YH/0247). Healthy pre-pandemic control samples were used under the NHSBT ethics, providing donor consent for their samples to be used in research. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupporting metadata are on-line at Figshare, DOI: 10.6084/m9.figshare.12278249